# Signos

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/signos

- Industry: Healthcare IT
- Headquarters: Burlingame, US
- Website: www.signos.com/
- Total disclosed funding: $37M
- Latest round: Series B (Jun 19, 2023)
- Investors on record: 7

## About

Signos, Inc. is a US-based company focused on continuous glucose monitoring technology that helps individuals understand their metabolism and achieve healthier dietary choices. Founded in 2020 in Burlingame, US, Signos, Inc. specializes in metabolic health solutions. The company is co-founded by Pierre Wehbe, Sharam Fouladgar-Mercer, and William Dixon, with Sharam Fouladgar-Mercer serving as the CEO. In May 2026, Signos, Inc. raised USD 20 million in venture funding from GV, Dexcom Ventures, and Blue Cross Blue Shield of Alabama. Signos provides advanced continuous glucose monitoring (CGM) technology designed to assist users in tracking their metabolic responses to food. Their primary offering integrates the Dexcom G7 sensor with the Signos app, delivering real-time glucose readings and personalized dietary feedback. The platform is aimed at health-conscious consumers focused on weight management and improved metabolic health, operating in key markets including the United States. Signos generates revenue through a subscription model, offering users access to its mobile application, personalized nutrition guidance, and essential hardware like the Dexcom G7 sensor. Membership plans are tailored for individual consumers, emphasizing long-term health and wellness, and facilitate direct-to-consumer transactions with their comprehensive glucose monitoring and coaching solutions. The company will use the May 2026 funding to enhance AI-driven product features, to scale user growth, and to expand distribution and accelerate adoption.

## Funding rounds

- Series B, Jun 19, 2023, $20M — GV, Cheyenne Ventures, Samsung NEXT Ventures, Dexcom Ventures
- Series A, Nov 10, 2021, $13M — GV
- Seed, Jan 1, 2021, $4M — Courtside Ventures, 1984 Ventures, Tau Ventures

## Investors

- Courtside Ventures (https://capitalatlas.ai/funds/courtside-ventures) — Seed
- 1984 Ventures (https://capitalatlas.ai/funds/1984-ventures) — Seed
- Tau Ventures — Seed
- GV (https://capitalatlas.ai/funds/gv) — Series A, Series B
- Cheyenne Ventures (https://capitalatlas.ai/funds/cheyenne-ventures) — Series B
- Samsung NEXT Ventures (https://capitalatlas.ai/funds/samsung-next-ventures) — Series B
- Dexcom Ventures (https://capitalatlas.ai/funds/dexcom-ventures) — Series B